> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Niagen Bioscience Posts $1.2 Million Loss As Quarterly Sales Fall 20% To $27.2 Million
- URL: https://www.bullished.co/niagen-bioscience-posts-1-2-million-loss-as-quarterly-sales-fall-20-to-27-2-million-46f6e432/
- Published: 2026-11-04T21:06:14.000Z
- Updated: 2026-11-04T21:06:14.000Z
- Description: Ingredient sales fell to $3.8 million from $6.9 million, and the CEO again called 2026 an investment year.
- Author: Matteo Parrino
- Tags: SEC Filings, NAGE, Industry: Healthcare

Niagen Bioscience, which sells the Tru Niagen supplement and supplies its Niagen vitamin B3 ingredient to other makers, reported [third-quarter net sales of $27.2 million](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000057/ex991pressrelease-q32026.htm?ref=bullished.co), down 20% from $34.0 million a year earlier, and a $1.2 million net loss. It earned $4.6 million in the same quarter of 2025.

## Ingredients drag, costs climb

Tru Niagen brought in $23.3 million, which the company's growth table shows was down 10% from a year earlier. Ingredient sales dropped to $3.8 million from $6.9 million. Sales on the company's own website rose 13%.

The loss was $0.01 per share, against $0.06 basic a year ago. Adjusted EBITDA, earnings before interest, taxes and certain other items, fell to $0.5 million from $6.4 million.

Gross margin was 62.9%, from 64.5% a year earlier. Operating expenses rose to $18.7 million from $17.7 million, with general and administrative costs up to $8.2 million from $7.1 million. The company swung to an operating loss of $1.6 million from $4.2 million of operating income.

For the first nine months, net income was $6.1 million, against $13.3 million a year earlier. That figure includes a $4.8 million gain from selling the analytical reference standards business in February.

## A cash cushion and an investment year

The company generated $2.6 million of operating cash flow in the quarter and ended September with $69.5 million in cash and no borrowings. Cash was $66.7 million at the end of June.

"As stated before, we view 2026 as an investment year," CEO Rob Fried said, adding that progress across consumer health, ingredients, injectables, skincare and pharmaceuticals is "a strong springboard for meaningful growth in 2027 and beyond."

The quarter included launches of an at-home Niagen injection kit through its Niagen Plus telehealth platform, a skincare product called Niagen NanoCloud, a brand campaign featuring surfer Kelly Slater, and Tru Niagen sales on Walmart.com and at nearly 300 GNC and Sam's Club stores. The company also engaged Red Sky Partners to help advance NB4168, its drug candidate for rare genetic and aging-related diseases, and signed a start-up agreement with Mass General Brigham to plan a clinical trial of Niagen.

## What management expects this year

The company expects direct website revenue to grow 15% to 20% for 2026 and overall e-commerce to grow about 5%. It expects the ingredient business to finish below last year, mainly because key ingredient partners are buying less amid competitive market dynamics. It said it added ingredient partners in the quarter and expects more.

It plans to introduce a lower-cost patented NR salt form to cut cost of goods sold. Operating expenses are expected to keep rising. Niagen Plus growth and new skincare partnerships should become meaningful contributors beginning in 2027, the company said.

Management held a webcast at 4:30 p.m. Eastern on Wednesday to discuss the results.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Niagen Bioscience, Inc. (NAGE)](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000057/cdxc-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex991pressrelease-q32026.htm — Niagen Bioscience, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000057/ex991pressrelease-q32026.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex992earningspresentatio.htm — Niagen Bioscience, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001386570/000138657026000057/ex992earningspresentatio.htm?ref=bullished.co) — SEC EDGAR